Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results

Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer